DGD Pharmaceuticals, Corp. is a team of passionate, committed, and experienced drug developers working to transform DGD1202, a first-in-class EGFR degrader, into a therapeutic reality.
- Headquartered in Chicago, IL
- Collaboration partnership with University of Michigan
- A Subsidiary Company of MAIA Biotechnology, Inc.
To use cutting edge science to develop treatment options for patients resistant to currently available therapies.